Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Thejew on May 05, 2019 3:55pm

113 Views

Post# 29712598

RE:RE:RE:2nd cohort update

I totaslly disagree, because GW was already worth like 3B during that time frame. Kalytera MC is at a ridiculously low 10M. Because it is so insanely undervalued right now I could see a massive run from these levels once Phase2 is done.

Also think about it like this, lets say with good phase 3 results in two years we could be at $1, our market cap would still only be at 500M roughly, still a fraction of GW, which would be worth over ten times that.

"They were in PH III as of May 2017

March 2016 looks like they were in PH 2b and the SP had just doubled to $141 from a positive 120 person trial.

So, without going into it deeper it looks like we would see a bumb but not a blowout."

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?